|
CA2608474C
(en)
*
|
2005-05-17 |
2019-11-12 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
EP1777294A1
(de)
*
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
|
|
PT2529747T
(pt)
|
2005-12-02 |
2018-05-09 |
Icahn School Med Mount Sinai |
Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
|
|
CA2636111C
(en)
|
2006-01-13 |
2018-04-03 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
|
WO2008089144A2
(en)
*
|
2007-01-12 |
2008-07-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Improved dna vaccination protocols
|
|
PT2160401E
(pt)
|
2007-05-11 |
2014-10-30 |
Altor Bioscience Corp |
Moléculas de fusão e variantes de il-15
|
|
AU2016206235B2
(en)
*
|
2007-06-27 |
2017-04-20 |
Novartis Ag |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
WO2009002562A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Marine Polymer Technologies, Inc. |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
|
EP3135294B1
(de)
|
2009-08-14 |
2020-06-03 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Verwendung von il-15 zur erhöhung der thymusleistung und zur behandlung von lymphopenie
|
|
KR20120093163A
(ko)
*
|
2009-09-14 |
2012-08-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
DK3327040T3
(da)
|
2010-09-21 |
2021-09-20 |
Altor Bioscience Corp |
Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
|
|
US20130302276A1
(en)
|
2010-10-22 |
2013-11-14 |
Dana-Farber Cancer Insitute Inc., |
Discovery of regulatory t cells programmed to suppress an immune response
|
|
LT2665486T
(lt)
*
|
2011-01-18 |
2020-04-10 |
Bioniz, Llc |
Kompozicijos, skirtos gama-c-citokino aktyvumui moduliuoti
|
|
EP2537933A1
(de)
*
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP2788021B1
(de)
|
2011-12-09 |
2017-01-18 |
Bavarian Nordic A/S |
Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
|
|
WO2013184938A2
(en)
*
|
2012-06-08 |
2013-12-12 |
Alkermes. Inc. |
Fusion polypeptides comprising mucin-domain polypeptide linkers
|
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
|
NZ630790A
(en)
*
|
2012-10-24 |
2016-11-25 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
GEP20196976B
(en)
|
2013-03-14 |
2019-06-10 |
Sloan Kettering Cancer Center Memorial |
Newcastle disease viruses and uses thereof
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
PL2986312T3
(pl)
*
|
2013-04-19 |
2022-04-19 |
Cytune Pharma |
Oparte na cytokinie leczenie z ograniczeniem zespołu przesiąkania naczyniowego
|
|
EP3783098A1
(de)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
|
|
EP4269441A3
(de)
|
2013-08-08 |
2024-01-24 |
Cytune Pharma |
Il-15- und il-15r-aplha-sushi-domänenbasierte modulokine
|
|
EP3659622A1
(de)
*
|
2013-08-08 |
2020-06-03 |
Cytune Pharma |
Kombinierte pharmazeutische zusammensetzung
|
|
JP6484634B2
(ja)
|
2014-01-08 |
2019-03-13 |
シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
Ｉｌ−１５ヘテロ二量体タンパク質及びその用途
|
|
CN113603788A
(zh)
*
|
2014-01-15 |
2021-11-05 |
卡德门企业有限公司 |
免疫调节剂
|
|
EP3441084A1
(de)
|
2014-02-27 |
2019-02-13 |
Viralytics Limited |
Onkolytisches virus und immunstimulator zur kombinationsbehandlung von krebs
|
|
EP2915569A1
(de)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
|
|
AP2016009475A0
(en)
|
2014-03-28 |
2016-09-30 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
|
EP3160498B1
(de)
|
2014-06-30 |
2021-10-06 |
Altor BioScience Corporation |
Il-15-basierte moleküle und verfahren zur verwendung davon
|
|
JP6655061B2
(ja)
|
2014-07-29 |
2020-02-26 |
ノバルティス アーゲー |
状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン
|
|
CA2957958C
(en)
|
2014-08-27 |
2023-10-17 |
Harvey Cantor |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
KR102609197B1
(ko)
*
|
2014-12-19 |
2023-12-05 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
인터류킨 15 단백질 복합체 및 그의 용도
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10273280B2
(en)
|
2015-02-27 |
2019-04-30 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US11655452B2
(en)
*
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3350205A1
(de)
|
2015-09-16 |
2018-07-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Spezifisches interleukin-15 (il-15)-antagonistenpolypeptid und verwendungen davon zur behandlung von entzündungs- und autoimmunerkrankungen
|
|
BR112018008293A2
(pt)
|
2015-10-30 |
2018-10-30 |
Cancer Research Tech Ltd |
expansão de células t gama delta não hematopoiéticas residentes no tecido e o uso dessas células
|
|
EP3387013B1
(de)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Cd3 und psma bindende heterodimere antikörper
|
|
EP3389712B1
(de)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antikörpermoleküle gegen pd-1 und verwendungen davon
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
EP3468581A1
(de)
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen
|
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
|
EP3474867A4
(de)
|
2016-06-24 |
2020-05-20 |
iCell Gene Therapeutics LLC |
Chimäre antigenrezeptoren (cars) zusammensetzungen und verfahren zur verwendung davon
|
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
WO2018013855A2
(en)
|
2016-07-14 |
2018-01-18 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018071919A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
|
|
JP7492336B2
(ja)
|
2016-10-21 |
2024-05-29 |
アルター・バイオサイエンス・コーポレーション |
多量体ｉｌ－１５に基づく分子
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
JP7288401B2
(ja)
*
|
2017-01-10 |
2023-06-07 |
プレシゲン，インコーポレイテッド |
新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
|
|
EP3589308A1
(de)
|
2017-02-28 |
2020-01-08 |
Sanofi |
Therapeutische rns
|
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
EP3600356A4
(de)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
Verkürzte chimäre nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen
|
|
SG11201909949XA
(en)
|
2017-05-24 |
2019-11-28 |
Pandion Therapeutics Inc |
Targeted immunotolerance
|
|
AU2018288814A1
(en)
*
|
2017-06-21 |
2020-02-06 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods thereof
|
|
CN111132733A
(zh)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
|
|
CN111432836A
(zh)
|
2017-09-05 |
2020-07-17 |
转矩医疗股份有限公司 |
治疗性蛋白质组合物及其制备和使用方法
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
AU2018388583A1
(en)
|
2017-12-19 |
2020-06-11 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
KR20200100098A
(ko)
|
2017-12-19 |
2020-08-25 |
젠코어 인코포레이티드 |
조작된 il-2 fc 융합 단백질
|
|
EP3759129A1
(de)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15-varianten und verwendungen davon
|
|
TW202003011A
(zh)
|
2018-03-26 |
2020-01-16 |
美商艾爾特生物科技責任有限公司 |
抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
|
CN110437339B
(zh)
*
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CN111867630B
(zh)
|
2018-06-17 |
2023-10-13 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
US20220106374A1
(en)
*
|
2018-06-22 |
2022-04-07 |
Cugene Inc |
Novel interleukin-15 (il-15) fusion proteins and uses thereof
|
|
CN110862967A
(zh)
*
|
2018-08-27 |
2020-03-06 |
天津天锐生物科技有限公司 |
一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
|
|
KR20210069639A
(ko)
|
2018-08-30 |
2021-06-11 |
에이치씨더블유 바이올로직스, 인크. |
단일-사슬 키메라 폴리펩타이드 및 이의 용도
|
|
AU2019328575A1
(en)
*
|
2018-08-30 |
2021-02-25 |
HCW Biologics, Inc. |
Single-chain and multi-chain chimeric polypeptides and uses thereof
|
|
JP7479383B2
(ja)
|
2018-09-27 |
2024-05-08 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたサイトカインポリペプチド
|
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
EP3877509A1
(de)
|
2018-11-08 |
2021-09-15 |
GammaDelta Therapeutics Limited |
Verfahren zur isolierung und erweiterung von zellen
|
|
GB201818243D0
(en)
|
2018-11-08 |
2018-12-26 |
Gammadelta Therapeutics Ltd |
Methods for isolating and expanding cells
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
|
MX2021010670A
(es)
|
2019-03-05 |
2021-11-12 |
Nkarta Inc |
Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
|
|
US20220218789A1
(en)
|
2019-05-10 |
2022-07-14 |
Nant Holdings Ip, Llc |
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
|
|
CA3136241A1
(en)
|
2019-05-20 |
2020-11-26 |
Ulrich Moebius |
Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases
|
|
TW202110885A
(zh)
|
2019-05-20 |
2021-03-16 |
美商潘迪恩治療公司 |
靶向ＭＡｄＣＡＭ之免疫耐受性
|
|
EP4013792A4
(de)
*
|
2019-08-15 |
2023-10-04 |
IGM Biosciences Inc. |
Immunstimulierende multimere bindungsmoleküle
|
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
JP2022554187A
(ja)
*
|
2019-10-24 |
2022-12-28 |
ミノトール セラピューティクス インコーポレイテッド |
キメラサイトカイン改変抗体およびその使用方法
|
|
CN111690068B
(zh)
*
|
2019-11-13 |
2022-04-19 |
中国科学技术大学 |
一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
|
|
JP2023502712A
(ja)
*
|
2019-11-21 |
2023-01-25 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
|
|
US20230093155A1
(en)
*
|
2019-12-13 |
2023-03-23 |
Cugene Inc |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
EP4107187A1
(de)
|
2020-02-21 |
2022-12-28 |
Pandion Operations, Inc. |
Gewebegezielte immuntoleranz mit einem cd39-effektor
|
|
GB202006989D0
(en)
|
2020-05-12 |
2020-06-24 |
Gammadelta Therapeutics Ltd |
Methods for isolating gamma delta t cells
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN114057889B
(zh)
*
|
2020-07-30 |
2023-11-10 |
深圳市北科生物科技有限公司 |
二硫键稳定的IL15-IL15Rα复合物及其应用
|
|
WO2022040482A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CN116134140A
(zh)
*
|
2020-09-01 |
2023-05-16 |
上海药明生物技术有限公司 |
长效作用的il-15及其用途
|
|
IL302313A
(en)
|
2020-10-26 |
2023-06-01 |
Cytune Pharma |
IL-2/IL-15RBY agonist for the treatment of non-melanoma skin cancer
|
|
US20230390361A1
(en)
|
2020-10-26 |
2023-12-07 |
Cytune Pharma |
Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(de)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Cd3 und gpc3 bindende heterodimere antikörper
|
|
GB202105113D0
(en)
|
2021-04-09 |
2021-05-26 |
Gammadelta Therapeutics Ltd |
Novel method
|
|
AU2022299404A1
(en)
|
2021-06-23 |
2023-12-07 |
Cytune Pharma |
Interleukin 15 variants
|
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
TW202328434A
(zh)
|
2021-08-03 |
2023-07-16 |
英商伽馬三角洲療法有限公司 |
γδＴ細胞之工程改造及其組成物
|
|
KR20240043797A
(ko)
|
2021-08-13 |
2024-04-03 |
싸이튠 파마 |
암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
|
|
WO2023056915A1
(en)
*
|
2021-10-08 |
2023-04-13 |
Suzhou Abogen Biosciences Co., Ltd. |
Polynucleotides encoding interleukin-12 (il-12) and related composition and methods thereof
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
WO2023194911A1
(en)
|
2022-04-04 |
2023-10-12 |
Gammadelta Therapeutics Ltd |
Cells expressing an anti-mesothelin car
|
|
WO2023194915A1
(en)
|
2022-04-04 |
2023-10-12 |
Gammadelta Therapeutics Ltd |
Novel gene armoring
|
|
GB202204926D0
(en)
|
2022-04-04 |
2022-05-18 |
Gammadelta Therapeutics Ltd |
Method for expanding gammadelta T cells
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|